ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS, which enables drug discovery through a combination of protein biology, physics, and supercomputing. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's disease; PMN267 for the treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy. The company also develops PNM440, an alpha-synuclein vaccine for treating multiple synucleinopathies; and PMN311, an amyloid-beta vaccine for the treatment of Alzheimer's. In addition, it is developing therapies for frontotemporal lobar degeneration, Huntington's disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. is headquartered in Toronto, Canada.…
ProMIS Neurosciences Licenses Next-Generation TXP1 Brain-Selective Shuttling Technology from Ossianix to Expand PMN310 Franchise and Pipeline
ProMIS Neurosciences (NASDAQ: PMN) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 10 employees.
The shares were at 3.160 USD on 20 November 2026, down 68.4% over 52 weeks. Its 52-week range is 2.780 USD to 27.40 USD: the price is 88.5% below the high and 13.7% above the low.
Its market capitalisation is 28.43M USD.
ProMIS Neurosciences reports an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 53.46M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. The next earnings report is expected on 18 March 2027.